AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00004897
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02287857
Drug: Domestic Tenofovir Disoproxil Fumarate Tablets
RxNorm normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 Domestic Tenofovir Disoproxil Fumarate Tablets and 1 blank Tenofovir Disoproxil Fumarate Tablets of Gilead
Trial: NCT02287857
Drug: Tenofovir Disoproxil Fumarate Tablets of Gilead
RxNorm normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 blank Domestic Tenofovir Disoproxil Fumarate Tablets and 1Tenofovir Disoproxil Fumarate Tablets of Gilead
Trial: NCT04154735
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A chemotherapy medication commonly used in the treatment of leukemia and lymphoma
Trial: NCT04154735
Drug: Mesna
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
Trial: NCT04154735
Drug: Alemtuzumab
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A protein that kills the immune cells that are thought to be causing Crohn's; it is commonly used in the treatment of leukemia and lymphoma
Trial: NCT04154735
Drug: G-CSF
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
Trial: NCT01020864
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab 500 mg/m² i.v. day 1, every 2nd week
Trial: NCT01020864
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin AUC = 3 i.v. day 1, every 21nd week
Trial: NCT01020864
Drug: Vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinorelbine 25 mg/m² i.v. day 1, every 2nd week
Trial: NCT00004897
Drug: hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04154735
Drug: Rifaximin
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An antibiotic used to treat irritable bowel syndrome and relapsing C. difficile infection; it inhibits DNA-dependent RNA polymerase
Trial: NCT04154735
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A medication which suppresses the immune system and inhibits T-lymphocytes; commonly used to lower the risk of organ rejection following transplant
Trial: NCT04766307
Drug: Interleukin-2
RxNorm normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin 2 (IL-2) is a pleiotropic cytokine that is produced after antigen activation and plays crucial roles in the immune response. IL-2 secreted by activated T cells is central to the development of an immune response to infection, promoting the differentiation and proliferation of lymphoid cells. This hydrophobic molecule and the various cytokines that it elicits regulates the behavior of T and B lymphocytes, monocytes/macrophages, natural killer (NK) cells, and neutrophils. IL-2 therapy regimens are expected to limit mycobacterial replication. Early clinical trials with IL-2 demonstrated that IL-2 immunotherapy may be useful in controlling infectious disease.
Trial: NCT02331823
Drug: Isoniazid Aminosalicylate Tablets
RxNorm normalized name: aminosalicylate
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a regimen consists of 5 anti-TB drugs (Isoniazid Aminosalicylate Tablets+pyrazinamide tablets+ethambutol tablets+rifabutin capsules+moxifloxacin tablets)to treat retreatment pulmonary tuberculosis patients. The total treatment course is 5 months.
Trial: NCT04173585
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib is a small molecule dipeptide binding the catalytic site of the 26 S proteasome. It acts as a potent, reversible, and specific inhibitor of proteasomes and thus impairs the degradation of ubiquitinated proteins. It has demonstrated anti-neoplastic activity in myeloma and lymphoma. It is approved and widely used in multiple myeloma both for first line treatment and relapsed patients.
Trial: NCT01808534
Drug: palifosfamide
RxNorm normalized name: Palifosfamide
DrugBank: Palifosfamide (DB05668)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03887780
Drug: Rivaroxaban (Xarelto,Bay 59-7939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 15 mg and 20 mg (OD)
Trial: NCT04205604
Drug: 18F-Fluoro Dopa Imaging
RxNorm normalized name: 16alpha-(18F)Fluoro-17beta-estradiol
DrugBank: Fluoroestradiol F-18 (DB15690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imaging with 18F-Fluoro Dopa PET Imaging
Trial: NCT04173585
Drug: Gemtuzumab Ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Gemtuzumab Ozogamicin is a monoclonal antibody directed against the myeloid surface antigen CD33. The antibody is linked to calicheamicin which serves as cytotoxic agent. For years, gemtuzumab ozogamicin has been tested in clinical AML trials. Though withdrawn from the US market in 2010, FDA approval was granted in September 2018, EU approval in April 2018 based on encouraging results from recent clinical trials using enhanced dosing schedules.
Trial: NCT02265874
Drug: Habitrol
RxNorm normalized name: Habitrol
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patch used daily for 28 weeks
Trial: NCT00276172
Drug: Natalizumab
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Natalizumab 300 mg by IV infusion, every 4 weeks, for up to 24 months
Trial: NCT00938314
Drug: human chorionic gonadotropin (hCG), then epoetin alfa (EPO)
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation
Trial: NCT00938314
Drug: human chorionic gonadotropin (hCG), then epoetin alfa (EPO)
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation
Trial: NCT01764672
Drug: Methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dose 40mg (2 x 20mg)
Trial: NCT02400788
Drug: Resminostat
RxNorm normalized name: resminostat
DrugBank: Resminostat (DB12392)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02400788
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04789135
Drug: Ozone
RxNorm normalized name: OZONE
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment consists of direct instillation into the bladder of ozone gas, with concentration of 20µg / ml - 60ml via urethral catheter.
Trial: NCT03797625
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60mg/m2，D1，8
Trial: NCT03797625
Drug: DDP
RxNorm normalized name: DDP
DrugBank: Mitometh (DB12117)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60mg/m2，D1
Trial: NCT03797625
Drug: Endostar
RxNorm normalized name: Endostar
DrugBank: Endostar (DB11727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15mg/d，d1-d7 civ
Trial: NCT01394939
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 180 mg/m2 IV every 2 weeks.
Trial: NCT03787641
Drug: Protamine Sulfate
RxNorm normalized name: Protamine Sulfate
DrugBank: Protamine sulfate (DB09141)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Protamine Sulfate will be administered via an infusion pump to administer a 50 mg test doze, then 100 mg after 5 min waiting period. Following blood samples, additional alliquots of 50 mg will be measured to a maximum of 300 mg.
Trial: NCT01440803
Drug: Teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daily injection of 20 mcg teriparatide for the treatment of idiopathic osteoporosis for 24 months.
Trial: NCT04945122
Drug: Pitavastatin
RxNorm normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pitavastatin 4mg Qn
Trial: NCT04945122
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20mg Qn
Trial: NCT00107237
Drug: everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus was formulated as tablets of 2.5 mg and 5 mg strength and supplied in blister packs.
Trial: NCT03773042
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For induction and maintenance of sedation.
Trial: NCT03368170
Drug: Mesdopetam (IRL790)
RxNorm normalized name: Mesdopetam
DrugBank: Mesdopetam (DB16229)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesdopetam (IRL790) capsule
Trial: NCT00004796
Drug: lactulose
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02300935
Drug: trametinib
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02300935
Drug: nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01670890
Drug: TMZ
RxNorm normalized name: TMZ
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients were treated with TMZ alone,Oral TMZ 50mg/m2/day,day 1 to 28,for 6 cycles
Trial: NCT00100464
Drug: Paroxetine
RxNorm normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03004703
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Active drug: Tocilizumab, 20 mg/ml; 14 ml (280 mg) dissolved in 100 ml NaCl 0.9 % i.v. once.
Trial: NCT03004703
Drug: Sodium chloride 0.9%
RxNorm normalized name: SODIUM CHLORIDE 0.9% INJ
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo: Sodium chloride 0.9%; 100 ml i.v. once.
Trial: NCT00225511
Drug: Effexor XR
RxNorm normalized name: Effexor XR
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00225511
Drug: Milnacipran
RxNorm normalized name: MILNACIPRAN
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03047057
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Lidocaine infusion
Trial: NCT03047057
Drug: IV normal saline
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV normal saline infusion
Trial: NCT03557281
Drug: Rifafour e-275
RxNorm normalized name: E-EPA
DrugBank: Icosapent ethyl (DB08887)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rifafour e-275 will be administered
Trial: NCT00891605
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 175 mg/m2 over 3 hours of paclitaxel will be given by intravenous infusion on Day 1 of each 21 day cycle.~Note - The dose and schedule is subject to change based on the toxicities observed.
Trial: NCT00659204
Drug: nano-silver gel exposed
RxNorm normalized name: benzalkonium
DrugBank: Silver nitrate (DB11080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SilvaSorb® gel applied topically to the hands with a limited exposure time of 10 minutes
Trial: NCT00659204
Drug: alcohol-based hand gel
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Purell gel applied topically to the hands with a limited exposure time of 10 minutes
Trial: NCT03290235
Drug: PEG-somatropin
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/kit
Trial: NCT02115464
Drug: Metformin plus Chemo-radiotherapy
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 2000 mg a day for 12 months plus cisplatin-based chemotherapy with or without consolidation with standard radiotherapy of 60-63 Gy for 6 weeks.
Trial: NCT01315990
Drug: FOLFIRI + Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1. Cetuximab (Erbitux® )- Cetuximab is a recombinant IgG1 chimeric monoclonal antibody directed against human epidermal growth factor receptor (EGFR).~2. FOLFIRI regimen~Administration Schedule:~Cetuximab at a initial dose 400 mg/sqm (first week), then 250 mg/sqm on day 1 and 8 Background Chemotherapy (every two weeks)~* Irinotecan 180 mg/m² iv , 90 min on day 1~* Folic acid (racemic) 400 mg/m², 120 min on day 1~* 5-FU 400 mg/m² bolus on day 1~* 5-FU 2400 mg/m² iv over 46 h on day 1 to 2
Trial: NCT03535753
Drug: Decitabine and R-GDP
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine and R-GDP
Trial: NCT00737867
Drug: Vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day 1: Vinorelbine capsules 60 mg/m2 Day 8: Vinorelbine capsules 60 mg/m2
Trial: NCT00737867
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day 1: Gemcitabine infusion 1000 mg/m2 Day 8: Gemcitabine infusion 1000 mg/m2
Trial: NCT00737867
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day 1: Carboplatin infusion AUC = 5 (Calvert's formula)
Trial: NCT00152425
Drug: Certolizumab Pegol (CDP870)
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02602327
Drug: Tas-102
RxNorm normalized name: TAS-102
DrugBank: TAS-102 (DB08937)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nucleoside antitumor agent consisting of α,α,α-trifluorothymidine (FTD) and 5-chloro-6-(2-iminopyrrolidin-1-yl) methyl-2,4 (1H,3H)-pyrimidinedione hydro chloride (TPI) at a molar ratio of 1:0.5.
Trial: NCT01902966
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting dose: 20 mg is taken by mouth twice a day (40 mg/day).
Trial: NCT00531804
Drug: gantenerumab
RxNorm normalized name: Gantenerumab
DrugBank: Gantenerumab (DB12034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered iv at escalating doses (7 cohorts)
Trial: NCT03706053
Drug: Midodrine Hydrochloride
RxNorm normalized name: Midodrine Hydrochloride
DrugBank: Midodrine (DB00211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Midodrine Hydrochloride, enteral, 10 or 20 mg
Trial: NCT00055952
Drug: exatecan mesylate
RxNorm normalized name: mesylate
DrugBank: Exatecan (DB12185)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02908516
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 doses of 1.95 g TXA orally, once in the ED and another dose pre-operatively.
Trial: NCT04677712
Drug: Arnica Gel
RxNorm normalized name: Arnica Gel
DrugBank: Arnica montana (DB14297)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants used Arnica Gel Patches (Arnica montana 50% and Ledum palustre) immediately after the CCH-aaes injection to the right buttock.
Trial: NCT00264108
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Either 150 ug once weekly or 500 ug once every 3 wks, variable treatment length.
Trial: NCT00264108
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40,000 IU once weekly, variable treatment length.
Trial: NCT02368717
Drug: Mesalazine Enema
RxNorm normalized name: mesalamine Enema
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00530946
Drug: Amlodipine 2.5mg/Atorvastatin 5mg
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single pill combination, dosed once daily for 8 weeks
Trial: NCT00530946
Drug: Amlodipine 2.5mg/Atorvastatin 10mg
RxNorm normalized name: AMLODIPINE 2.5MG/ATORVASTATIN 10MG TAB
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single pill combination, dosed once daily for 8 weeks
Trial: NCT03756038
Drug: Lorazepam
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The purpose of this study is to determine whether a single low dose of Lorazepam/Ativan (1mg) can relieve pain and reduce negative mood in the emergency department and for 2 weeks after emergency department treatment.
Trial: NCT00777569
Drug: Nicotine free cigarettes
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quest Step 2 contains 0.05 mg nicotine
Trial: NCT00777569
Drug: Extra-low nicotine cigarettes
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quest 2 cigarettes contains 0.3 mg nicotine
Trial: NCT00777569
Drug: Nicotine Lozenge
RxNorm normalized name: nicotine Lozenge Product
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 mg nicotine lozenge
Trial: NCT00413361
Drug: versus hydroxychloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: versus hydroxychloroquine
Trial: NCT00530946
Drug: Amlodipine 5mg/Atorvastatin 5mg
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single pill combination, dosed once daily for 8 weeks
Trial: NCT00530946
Drug: Amlodipine 5mg/Atorvastatin 10mg
RxNorm normalized name: AMLODIPINE 5MG/ATORVASTATIN 10MG TAB
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single pill combination, dosed once daily for 8 weeks
Trial: NCT00436839
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75mg/m² intravenously (day 1) every 21 days
Trial: NCT00436839
Drug: Mitoxantrone
RxNorm normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12mg/m² intravenously every 21 days
Trial: NCT00436839
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg orally given daily
Trial: NCT00783094
Drug: Tadalafil 2.5 mg
RxNorm normalized name: tadalafil 2.5 MG
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral, daily
Trial: NCT00783094
Drug: Tadalafil 5 mg
RxNorm normalized name: tadalafil 5 MG
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral, daily
Trial: NCT02469090
Drug: APL-130277
RxNorm normalized name: APL-502
DrugBank: APL-502 (DB17473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use to treat up to 5 OFF episodes per day
Trial: NCT06458803
Drug: Eltrombopag
RxNorm normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: patients receive oral eltrombopag at 25 to 75 mg once daily according to disease severity，with the treatment of DMARDs at minimal or routine dosages.
Trial: NCT03286842
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will be administered olaparib orally, twice daily at 300 mg. Two (2) 150 mg olaparib tablets should be taken at the same time each morning and evening of every day, approximately 12 hours apart.
Trial: NCT00005648
Drug: Gemcitabine with R115777
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: R115777 200 mg, oral, twice daily at 12-hour intervals throughout the study coadministered with gemcitabine, 1000 mg/m2, iv, every week for the first 7 weeks, followed by 1 week rest, and then every 3 out of 4 weeks thereafter for up to 5 years
Trial: NCT00005648
Drug: Gemcitabine with Placebo
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Placebo, oral, twice daily at 12-hour intervals throughout the study coadministered with gemcitabine, 1000 mg/m2, iv, every week for the first 7 weeks, followed by 1 week rest, and then every 3 out of 4 weeks thereafter for up to 5 years
Trial: NCT03382509
Drug: BI 1467335
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice Daily
Trial: NCT00145990
Drug: methacholine
RxNorm normalized name: Methacholine
DrugBank: Methacholine (DB06709)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03209219
Drug: Interferon Alfa-2A
RxNorm normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3×10\^6 IU， subcutaneous or intramuscular injection, qd for × 4 weeks, and qod thereafter